sacituzumab
gilead sciences
['tropics-02', 'bcsm', 'breast', 'sacituzumab']
pfs and response results presented from the phase 3 tropics-02 trial indicated sacituzumab govitecan-hziy may be favorable vs physician s choice of treatment for her2-low/her2 ihc0, hormone receptor positive metastatic breast cancer.#bcsm #esmo22 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.